Scenesse?

What is Scenesse?

Scenesse, also known as afamelanotide, is a skin melanin-inducing peptide administered via implant or injection. It was designed to increase melanin production in the skin [1].

How does it work?

Scenesse aims to reduce sun-induced erythema (redness) in individuals with erythropoietic protoporphyria (EPP) [2], a rare condition characterized by severe skin reactions to sunlight. EPP affects only a small number of people and is associated with symptoms like pain and blistering upon sun exposure.

How long has Scenesse been in development?

The Scenesse product has been in development for decades, and clinical trials started as far back as in the late 1990s.

When did Scenesse gain approval?

In 2018, Scenesse gained approval from regulatory bodies in the UK, Europe, and South Africa [3] under the accelerated pathway for rare and orphan disease treatments. However, it has yet to receive approval in the USA.

When does the patent expire?

DrugPatentWatch.com notes that Afamelanotide's (Scenesse) patent has been issued until 2037 [4]

References:

[1] http://www.drugpatentwatch.com/patent/US-20130041353

[2] https://www.bionamics.com/afamelanotide-erythropoietic-protoporphyria.php

[3] http://www.bionomics.co.uk/afamelanotide

[4] DrugPatentWatch.com: https://www.drugpatentwatch.com/drug/afamelanotide